Sectors
FBRX
Forte Biosciences, Inc.
76.83
21 x 76.84
15 x 76.85
bid
ask
+
0.01
0.01%
09:38 AM
timesize
| Ytd | 181.74% | |
| 1y | 631.02% |
76.81
day range
76.85
10.30
52 week range
76.98
| Open | 76.84 | Prev Close | 76.82 | Low | 76.81 | High | 76.85 | Mkt Cap | 1.57B |
| Vol | 122.87K | Avg Vol | 1.06M | EPS | -4.64 | P/E | -16.56 | Forward P/E | -19.02 |
| Beta | 2.62 | Short Ratio | 2.43 | Inst. Own | 82.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 38.47 | 200-d Avg | 28.34 | 1yr Est | 73.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-13 | 2026-06 | -0.88 | N/A | N/A | N/A |
| 2026-05-21 | 2026-03 | -1.16 | -1.24 | -0.08 | -6.90% |
| 2026-03-31 | 2025-12 | -1.42 | -1.45 | -0.03 | -2.11% |
| 2025-11-14 | 2025-09 | -1.04 | -0.99 | 0.05 | 4.81% |
| 2025-08-14 | 2025-06 | -1.21 | -0.96 | 0.25 | 20.66% |
| 2025-05-15 | 2025-03 | -0.89 | -1.37 | -0.48 | -53.93% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-28 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2026-07-21 | Barclays | Upgrade | Overweight | |
| 2025-11-25 | Evercore ISI Group | Upgrade | Outperform | |
| 2025-11-17 | Chardan Capital | Upgrade | Buy | Buy |
| 2025-08-18 | Guggenheim | Upgrade | Buy | |
| 2025-08-15 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-30 | RILEY ANTONY A | Chief Financial Officer | 42.60K | Conversion of Exercise of derivative security |
| 2026-06-30 | WAGNER PAUL A | Chief Executive Officer | 85.48K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Federated Hermes, Inc. | 1.77M | 135.63M | 8.62% |
| 2026-03-30 | Fred Alger Management, LLC | 1.27M | 97.87M | 6.22% |
| 2026-06-29 | Blackrock Inc. | 1.22M | 93.94M | 5.97% |
| 2026-03-30 | Orbimed Advisors LLC. | 1.20M | 91.95M | 5.84% |
| 2026-03-30 | Janus Henderson Group PLC | 1.19M | 91.27M | 5.80% |
| 2026-03-30 | Affinity Asset Advisors, Llc | 1.01M | 77.73M | 4.94% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.25M | 96.14M | 6.11% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 832.10K | 63.92M | 4.06% |
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 502.79K | 38.62M | 2.46% |
| 2026-04-29 | ALGER FUNDS-Alger Small Cap Focus Fund | 496.06K | 38.11M | 2.42% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 478.15K | 36.73M | 2.33% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 393.73K | 30.25M | 1.92% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2024-08-28 |
| 1 : 15 | 2020-06-16 |